Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Acetate,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Recipient : Milla Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL
Details : Sodium Acetate-generic Injection is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.
Product Name : Sodium Acetate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2024
Lead Product(s) : Sodium Acetate,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Recipient : Milla Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Acquisition
Woodward Pharma Services LLC Acquires LOVAZA(R) Capsules
Details : Woodward Pharma Services LLC, has acquired Lovaza (LO-VEY-ZA) soft gelatin capsules indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia from GlaxoSmithKline...
Product Name : Lovaza
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Omega-3-Acid Ethyl Esters 90,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
